Abstract

Erectile dysfunction is more prevalent in aging males, and its occurrence is increased in the presence of associated cardiovascular comorbidities. Available treatments include a wide range of options to regain erectile function and thereby improve patients’ quality of life. Oral phosphodiesterase 5 inhibitors are considered to be the first line of therapy for the majority of causes of erectile dysfunction, due to their high efficacy, ease of use and acceptable safety profile. Second-line therapies include vacuum tumescence devices, intraurethral suppository or intracavernosal injections with various vasoactive agents. Penile prosthesis implantation has the highest rate of success but is reserved as a final treatment option due to cost, invasiveness and irreversibility. Gene therapy for erectile dysfunction is in the early stages of investigation and will require further basic clinical studies before being considered as a viable option. Overall, available treatment options for erectile dysfunction can successfully restore sexual function in most men. Future therapies will offer new categories of drugs that exploit novel mechanisms of action with even greater efficacy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call